Table 1.
Comparison of Baseline Clinicopathological Characteristics Between the Training and Validation Cohorts
| Variables | All | Training | Validation | P value |
|---|---|---|---|---|
| N = 1259 | N = 883 | N = 376 | ||
| Age(years), median (IQR) | 48.0 (41.0–57.0) | 48.0 (41.0–57.0) | 47.5 (41.0–56.0) | 0.395 |
| Age at diagnosis | 0.365 | |||
| ≤50 | 751 (59.7%) | 519 (58.8%) | 232 (61.7%) | |
| >50 | 508 (40.3%) | 364 (41.2%) | 144 (38.3%) | |
| T stage a | 0.614 | |||
| T1 | 444 (35.3%) | 320 (36.2%) | 124 (33.0%) | |
| T2 | 692 (55.0%) | 478 (54.1%) | 214 (56.9%) | |
| T3 | 65 (5.16%) | 43 (4.87%) | 22 (5.85%) | |
| T4 | 58 (4.61%) | 42 (4.76%) | 16 (4.26%) | |
| N stage a | 0.981 | |||
| N0 | 648 (51.5%) | 456 (51.6%) | 192 (51.1%) | |
| N1 | 338 (26.8%) | 238 (27.0%) | 100 (26.6%) | |
| N2 | 160 (12.7%) | 110 (12.5%) | 50 (13.3%) | |
| N3 | 113 (8.98%) | 79 (8.95%) | 34 (9.04%) | |
| Menstrual status | 0.316 | |||
| Premenopausal | 745 (59.2%) | 514 (58.2%) | 231 (61.4%) | |
| Postmenopausal | 514 (40.8%) | 369 (41.8%) | 145 (38.6%) | |
| Histological type | 1.000 | |||
| Others | 199 (15.8%) | 140 (15.9%) | 59 (15.7%) | |
| IDC | 1060 (84.2%) | 743 (84.1%) | 317 (84.3%) | |
| ER status | 0.867 | |||
| Negative | 354 (28.1%) | 250 (28.3%) | 104 (27.7%) | |
| Positive | 905 (71.9%) | 633 (71.7%) | 272 (72.3%) | |
| PR status | 0.405 | |||
| Negative | 452 (35.9%) | 324 (36.7%) | 128 (34.0%) | |
| Positive | 807 (64.1%) | 559 (63.3%) | 248 (66.0%) | |
| HER2 status | 0.410 | |||
| Negative | 886 (70.4%) | 628 (71.1%) | 258 (68.6%) | |
| Positive | 373 (29.6%) | 255 (28.9%) | 118 (31.4%) | |
| Ki-67 index b | 0.578 | |||
| <30 | 673 (53.5%) | 467 (52.9%) | 206 (54.8%) | |
| ≥30 | 586 (46.5%) | 416 (47.1%) | 170 (45.2%) | |
| SIS | 0.606 | |||
| 0 | 844 (67.0%) | 592 (67.0%) | 252 (67.0%) | |
| 1 | 368 (29.2%) | 261 (29.6%) | 107 (28.5%) | |
| 2 | 47 (3.73%) | 30 (3.40%) | 17 (4.52%) | |
| CONUT | 0.081 | |||
| 1 | 548 (43.5%) | 402 (45.5%) | 146 (38.8%) | |
| 2 | 436 (34.6%) | 303 (34.3%) | 133 (35.4%) | |
| 3 | 199 (15.8%) | 125 (14.2%) | 74 (19.7%) | |
| 4 | 65 (5.16%) | 46 (5.21%) | 19 (5.05%) | |
| 5 | 11 (0.87%) | 7 (0.79%) | 4 (1.06%) | |
| NLR, median (IQR) | 1.89 (1.46–2.46) | 1.88 (1.45–2.45) | 1.92 (1.48–2.47) | 0.376 |
| PLR, median (IQR) | 680 (504–933) | 668 (498–934) | 700 (522–933) | 0.755 |
| MLR, median (IQR) | 0.17 (0.13–0.23) | 0.17 (0.13–0.23) | 0.17 (0.12–0.23) | 0.756 |
| SII, median (IQR) | 421 (307–588) | 416 (300–586) | 434 (325–601) | 0.270 |
| SIRI, median (IQR) | 0.60 (0.41–0.90) | 0.61 (0.41–0.90) | 0.60 (0.40–0.87) | 0.612 |
| PNI, median (IQR) | 53.5 (50.6–56.3) | 53.6 (50.7–56.3) | 53.3 (50.4–56.2) | 0.986 |
| AAPR, median (IQR) | 0.71 (0.57–0.86) | 0.71 (0.58–0.87) | 0.71 (0.56–0.84) | 0.605 |
| BMI, median (IQR) | 23.0 (20.8–25.2) | 23.1 (20.9–25.3) | 22.8 (20.8–25.1) | 0.367 |
Notes: aDiagnosed based on the AJCC 2010 criteria (seventh edition). bThe Ki-67 index at diagnosis indicates DNA synthetic activity as measured using immunocytochemistry.
Abbreviations: IDC, invasive ductal carcinoma; IQR, interquartile ranges; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; BMI, body mass index; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; MLR, monocyte-lymphocyte ratio; SII, systemic immune inflammation index; PNI, prognostic nutritional index; SIRI, system inflammation response index; COUNT, controlling nutritional status; SIS, system inflammation score; AAPR, album-alkaline phosphatase ratio.